<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232439</url>
  </required_header>
  <id_info>
    <org_study_id>12511</org_study_id>
    <secondary_id>I2Z-MC-LAFC</secondary_id>
    <nct_id>NCT01232439</nct_id>
  </id_info>
  <brief_title>A Study of Brain Receptor Occupancy in Healthy Subjects</brief_title>
  <official_title>Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To measure the occupancy of brain kappa opioid receptors after single oral doses of
      LY2456302.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in brain kappa opioid receptor occupancy (RO) by positron emission tomography (PET)</measure>
    <time_frame>Baseline, after single dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, area under the curve (AUC)</measure>
    <time_frame>Days 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant effects</measure>
    <time_frame>Baseline to study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, concentration maximum (Cmax)</measure>
    <time_frame>Days 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>opioid receptor kappa antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>opioid receptor kappa antagonist</intervention_name>
    <description>Starting dose of 2 mg, administered orally, once.
The potential dose range for this study is 0.2 mg to 30 mg</description>
    <arm_group_label>opioid receptor kappa antagonist</arm_group_label>
    <other_name>LY2456302</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female

          -  Have clinical laboratory tests within normal reference ranges

          -  Have arterial and venous access sufficient to allow blood sampling

        Exclusion Criteria:

          -  Currently enrolled in, or discontinued within the last 30 days from a clinical trial

          -  History of severe allergies or multiple adverse drug reactions

          -  Have an abnormal ECG at screening visit

          -  Have abnormal sitting blood pressure

          -  Have an increased risk of seizures

          -  Current suicidal ideation

          -  Positive test for HIV, hepatitis C, or hepatitis B

          -  Women who are breast feeding

          -  Smoke more than 10 cigarettes per day, or equivalent

          -  Drink more than 5 cups of coffee per day, or equivalent

          -  Have a history of head injury

          -  Unable to undergo a MRI

          -  Suffer from claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

